摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-1H-quinolin-4-one | 727375-82-8

中文名称
——
中文别名
——
英文名称
1-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-1H-quinolin-4-one
英文别名
1-[4-[3-(3,5-dimethyl-1,2-oxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-(trifluoromethyl)pentyl]quinolin-4-one
1-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-1H-quinolin-4-one化学式
CAS
727375-82-8
化学式
C27H27F3N2O3
mdl
——
分子量
484.518
InChiKey
UXTPDIXNBNTLQU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.1
  • 重原子数:
    35
  • 可旋转键数:
    6
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    66.6
  • 氢给体数:
    1
  • 氢受体数:
    8

反应信息

  • 作为产物:
    描述:
    3,5-二甲基异恶唑-4-硼酸 、 1-[4-(3-bromophenyl)-2-hydroxy-4-methyl-2-trifluoromethylpentyl]-1H-quinolin-4-one 在 bis-triphenylphosphine-palladium(II) chloride caesium carbonate 作用下, 以 乙二醇二甲醚乙醇 为溶剂, 反应 0.08h, 生成 1-{4-[3-(3,5-dimethylisoxazol-4-yl)phenyl]-2-hydroxy-4-methyl-2-trifluoromethylpentyl}-1H-quinolin-4-one
    参考文献:
    名称:
    [EN] 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS
    [FR] DERIVES DE 1-PROPANOL ET 1-PROPYLAMINE ET LEUR UTILISATION EN TANT QUE LIGANDS DE GLUCOCORTICOIDE
    摘要:
    式(I)的化合物,其中R1、R2、R3、R4、R5、R6和X如式(IA)和式(IB)中所定义,或其异构体、前药、溶剂化合物或盐;含有这些化合物的药物组合物,以及使用这些化合物调节糖皮质激素受体功能的方法,以及使用这些化合物治疗由糖皮质激素受体功能介导或以炎症、过敏或增殖过程为特征的疾病状态或病况的方法。
    公开号:
    WO2004063163A1
点击查看最新优质反应信息

文献信息

  • Substituted pteridines for the treatment of inflammatory diseases
    申请人:Dollinger Horst
    公开号:US20060116372A1
    公开(公告)日:2006-06-01
    The invention relates to new pteridines which are suitable for the treatment of respiratory or gastrointestinal complaints or diseases, inflammatory diseases of the joints, skin or eyes, diseases of the peripheral or central nervous system or cancers, as well as pharmaceutical compositions which contain these compounds.
    该发明涉及新的黄素衍生物,适用于治疗呼吸系统或胃肠道疾病、关节、皮肤或眼部炎症性疾病、外周或中枢神经系统疾病或癌症,以及含有这些化合物的药物组合物。
  • Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
    申请人:Boehringer Ingelheim Pharmaceuticals, Inc.
    公开号:US20040162321A1
    公开(公告)日:2004-08-19
    Compounds of Formula (I) 1 wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof, pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by inflammatory, allergic, or proliferative processes in a patient using these compounds.
    该化合物的公式(I)1,其中R1,R2,R3,R4,R5,R6和X的定义如公式(IA)和公式(IB)中所述,或其互变异构体、前药、溶剂化物或盐,制备含有该化合物的药物组合物,并使用这些化合物调节糖皮质激素受体功能的方法以及治疗由糖皮质激素受体功能介导或以炎症、过敏或增生过程为特征的疾病状态或病情的方法。
  • COMPOSITIONS AND METHODS FOR TREATING, CONTROLLING, REDUCING, OR AMELIORATING INFLAMMATORY PAIN
    申请人:Ward Keith W.
    公开号:US20120316199A1
    公开(公告)日:2012-12-13
    A composition for treating, controlling, reducing, or ameliorating inflammatory pain comprises a dissociated glucocorticoid receptor agonist (“DIGRA”), a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable ester thereof. The composition can comprise an additional anti-inflammatory agent and can be formulated for topical application, injection, or implantation. It may be used in a method of managing post-surgical ocular pain such that it has lower risk of eliciting adverse side effects seen with other therapeutic agents.
    用于治疗、控制、减轻或改善炎症性疼痛的组合物包括解离型糖皮质激素受体激动剂(“DIGRA”)、其前药、其药学上可接受的盐或其药学上可接受的酯。该组合物可以包含额外的抗炎药物,并可制成局部应用、注射或植入剂。它可以用于管理术后眼部疼痛的方法,从而降低与其他治疗剂产生的不良副作用风险。
  • Compositions and methods for treating, controlling, reducing, or ameliorating infections and sequelae thereof
    申请人:BAUSCH & LOMB INCORPORATED
    公开号:EP2364707A2
    公开(公告)日:2011-09-14
    A composition for treating, controlling, reducing, ameliorating, or alleviating infections and their inflammatory sequelae comprises a dissociated glucocorticoid receptor agonist ('DIGRA') and an anti-infective agent, such as an antibacterial, antiviral, antifungal, antiprotozoal agent, or a combination thereof. The composition can be formulated for topical application, injection, or implantation.
    一种用于治疗、控制、减少、改善或减轻感染及其炎症后遗症的组合物包含一种解离糖皮质激素受体激动剂("DIGRA")和一种抗感染剂,如抗菌剂、抗病毒剂、抗真菌剂、抗原虫剂或其组合。该组合物可配制成外用、注射或植入剂。
  • 1-PROPANOL AND 1-PROPYLAMINE DERIVATIVES AND THEIR USE AS GLUCOCORTICOID LIGANDS
    申请人:Boehringer Ingelheim Pharmaceuticals Inc.
    公开号:EP1583745A1
    公开(公告)日:2005-10-12
查看更多